ABBV Ticker Curator

Multi-faceted drivers fueled ABBV's ~3% gain on Feb 27, outperforming pharma peers:

• $380M manufacturing investment in AI-equipped facilities for...

• Generali Investments boosted stake 38.4% in Q3 to 29,448 shares worth $6.8M, its 13th largest position (1.4% portfolio).
• Joins Vanguard (+1.9% to...

• Value Style Score B driven by forward P/E of 15.51
• Allergan acquisition cuts Humira reliance; Skyrizi & Rinvoq fuel growth
• 8 analysts raised FY2026 estimates; consensus at $14.49
• #3 Hold Rank with VGM B suggests strong potential

AbbVie ($ABBV) announced an update on its ongoing XEN45 gel stent clinical study for glaucoma, testing a new approach and highlighting eye care as a potential growth avenue beyond immunology/oncology.

Gubra's FY2025 revenue reached $398 million—a nearly tenfold increase—driven by the $2.2B AbbVie transaction, signaling major pipeline investment for AbbVie investors.

Institutional Investor Moves

• 🔥 Andra AP-fonden Boosts Holdings: Andra AP-fonden increased its stake in AbbVie by 43.4% in Q3, purchasing an...

• Recent close: US$224.69
• +0.2% last week, +0.3% last month
• -2.0% year to date
• +13.3% over the past period

• Andra AP-fonden grew its AbbVie holdings by 43.4% in Q3, adding 32,500 shares to reach 107,300 shares worth $24.84M.
• This move amid 70.23%...

ABBV dipped 0.98% to close at $224.69 after opening at $227.59, ranging 221.13-227.78 on 5.33M volume (82% of 6.47M avg).

• After-hours: Flat at $224.68
• Recent pullback: YTD -1.66%, 1Y -7.49%
• Investment hook: 3.08% yield ($1.73 div) amid dip

DOJ supports AbbVie in suit challenging Colorado’s drug discount law – a positive regulatory tailwind bolstering pricing power and revenue protection.

AbbVie's long-term prospects shine despite Humira's patent cliff:

• Immunology drivers Skyrizi and Rinvoq fuel growth through 2031 with no patent...

AbbVie boasts a solid 3.05% dividend yield, making it a prime pick for income seekers, with the next payout on May 15, 2026 (ex-date April 15, 2026).

Key Evercore take on ABBV:

• Tremfya advancing: Gaining market share, supporting 2026-2027 outlook as achievable.
• Caution ahead: Buy-side...

Intech cut ABBV holdings by 26.9% in Q3, selling 25,923 shares to hold 70,533 worth $16.3M.

• Small adds elsewhere: Ellenbecker +0.8% to 5,334...

Key contrasts for ABBV investors:

• MRK's superior outlook: Projected DCR of 2.57x in 2026 beats historical average and ABBV.
• ABBV's pressures:...

AbbVie stock approaches highs after fresh analyst calls, driven by double-digit growth in immunology and solid neuroscience momentum in the latest quarterly update. Strong buy signal for investors.

SEC Filings

• 🔥 10-K Annual Report: AbbVie filed its 10-K on 02/20/26, providing a comprehensive overview of the company for the past year.
• 🔥...

AbbVie's recent SEC sequence:

• Feb 20, 2026: Filed 10-K annual report, comprehensive past-year overview
• Feb 25, 2026: Filed for seven-part notes offering up to $8 billion

Timeline flags post-annual capital raise moves for investors.

ABBV draws positive analyst consensus:

• Average one-year price target $255.68/share signals 11.92% upside
• Trading at discount to fair value with...